ANIP Q2 2024 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$138M+18.4% YoY

Gross Profit

$80M58.2% margin

Operating Income

$5M3.7% margin

Net Income

-$2M-1.7% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

+0.4%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$13M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$921M

Total Liabilities

$440M

Stockholders' Equity

$481M

Cash & Equivalents

$240M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$138M	$117M	+18.4%
Gross Profit	$80M	$74M	+8.2%
Operating Income	$5M	$12M	-58.3%
Net Income	-$2M	$6M	-136.6%

Revenue Segments

Generics, Established Brands, and Other

$89M64%

Rare Disease

$49M36%

Geographic Segments

UNITED STATES

$138M100%